New gel injections aim to smooth cheek wrinkles
NCT ID NCT07344584
First seen Jun 24, 2026 · Last updated Aug 14, 2026 · Updated 4 times
Summary
This pilot study will test the safety and effectiveness of two injectable gels, GP0122 and GP0124, for reducing lines and wrinkles in the cheek area. About 60 adults with moderate to severe cheek wrinkles will receive the treatment and be followed for 12 months. The main goal is to check for side effects and pain, with secondary goals looking at wrinkle improvement.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Injectable gel (GP0122 and GP0124)
- What this could lead to
- If successful, this could lead to a new, safe option for reducing cheek wrinkles.
- What could go wrong
- This is a small, early pilot study with only 60 participants. It focuses on safety first, so effectiveness is not yet proven. Results may not apply to everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2026
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Adult males or non-pregnant, non-breastfeeding adult females. 1. Participants with a GCWS At Rest score of Moderate or Severe on EACH side of the face, or Participants with a CSQS-CL score of Moderate, Severe, or Very severe on EACH side of the face. 2. Intent to undergo treatment for correction of lines and wrinkles in the cheek region. 3. Willing to abstain from any other facial plastic, surgical or cosmetic procedures in the cheek area for the duration of the study (e.g., laser or chemical resurfacing, needling, facelift, lifting threads, radiofrequency etc.). Inclusion criteria 4-5 apply only to female participants of childbearing potential: 4. Agrees to use an acceptable form of effective birth control for the duration of the study and is willing to take a urine pregnancy test (UPT) at screening, baseline and prior to receiving any study treatment. 5. Negative UPT at the screening and baseline visits. Exclusion Criteria: 1. Known/previous allergy or hypersensitivity. 2. Known/previous allergy or hypersensitivity to local anesthetics. 3. Previous facial surgery (e.g., facelift) in the treatment area that in the Treating Investigator´s opinion. 4. Any previous aesthetic procedures or implants in the treatment area. 5. Presence of any disease or lesions in the treatment area. 6. An underlying known disease, a surgical or medical condition that would expose the participant to undue risk. 7. Use of concomitant medication that have the potential to prolong bleeding times. 8. Presence of any condition or situation, which in the opinion of the Treating Investigator makes the subject unable to complete the study per protocol. 9. Women who are pregnant or breast feeding, or women of childbearing potential who are not practicing adequate contraception or planning to become pregnant during the study period.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Wrinkle reduction are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Galderma Investigational Site #7049
Vancouver, V6H4E1, Canada
-
Galderma Investigational Site #8162
Woodbridge, L4L 8E2, Canada
-
Galderma Investigational Site #8379
Burlington, L7N3N2, Canada
-
Galderma Investigational Site #8688
Vancouver, V5ZRE1, Canada
-
Galderma Investigational Site #8689
Toronto, M543N8, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.